文献速递泌尿生殖与妇科肿瘤放疗

剂量提升调强放疗单用不放疗去势治疗中高危前列腺癌的长期结局

Long-term outcomes of dose-escalated intensity modulated radiation therapy alone without androgen deprivation therapy for patients with intermediate and high-risk prostate cancer.
PubMed 文献 · Adv Radiat Oncol · 2016-10-29

研究回顾2001年9月至2010年3月127例接受剂量提升放疗而未联合雄激素剥夺治疗(ADT)的中高危前列腺癌患者,中位随访6.5年,5年生化复发无生存率(bRFS)为89%、远处转移无生存率(DMFS)为96.1%、前列腺癌特异性死亡率为98.4%、总生存率(OS)为96.9%。多因素分析显示风险组和PSA最低值是bRFS的预测因素,神经周围侵犯、风险组和PSA最低值是DMFS的预测因素。结论提示预后良好的中危患者可能可单用剂量提升放疗而不加ADT,而高危、不良中危、神经周围侵犯及PSA最低值≥1ng/dL者结局较差,可能需要不同的治疗策略。

要点

  • 中高危前列腺癌单用剂量提升放疗不放疗ADT,5年bRFS为89%、DMFS为96.1%。
  • 风险组和PSA最低值是bRFS的独立预测因素。
  • 神经周围侵犯、风险组和PSA最低值预测DMFS。

核心结论

  • 预后良好的中危前列腺癌患者可能可接受剂量提升放疗而不联合ADT。
  • 高危和不良中危患者、有神经周围侵犯或PSA最低值≥1ng/dL者结局较差,可能需要不同的治疗策略。

研究设计与样本

  • 回顾性分析2001年9月至2010年3月127例接受剂量提升放疗而未联合ADT的中危或高危前列腺癌患者。

主要发现

  • 中位随访6.5年,全部患者5年估计bRFS为89%、DMFS为96.1%、前列腺癌特异性死亡率为98.4%、OS为96.9%。
  • 多因素分析中预测bRFS的因素包括风险组和PSA最低值。
  • 多因素分析中预测DMFS的因素包括神经周围侵犯、风险组和PSA最低值。

临床怎么用

  • 对预后良好的中危前列腺癌患者,可考虑单用剂量提升放疗而不加ADT。
  • 对高危、不良中危、有神经周围侵犯或PSA最低值≥1ng/dL的患者,应评估更强化或不同的治疗策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The addition of androgen deprivation therapy (ADT) to conventional radiation therapy improves overall survival (OS) in intermediate- and high-risk prostate cancer. The benefit of ADT to added to dose-escalated radiotherapy is less clear. The aim of this study was to report disease control outcomes and to identify prognostic variables associated with favorable outcomes in patients with intermediate- and high-risk prostate cancer treated with dose-escalated radiation therapy without ADT. METHODS AND MATERIALS: From September 2001 to March 2010, 127 patients with intermediate- or high-risk prostate cancer were treated with dose-escalated radiation otherapy without ADT. Biochemical recurrence-free survival (bRFS), distant metastases-free survival (DMFS), prostate cancer-specific mortality, and OS were assessed. Univariate and multivariate analyses using Cox regression modeling were performed. RESULTS: The median follow-up was 6.5 years, and the 5-year estimated bRFS, DMFS, prostate cancer-specific mortality, and OS for all patients was 89%, 96.1%, 98.4%, and 96.9% respectively. On multivariate analysis, factors that predict bRFS include risk group and PSA nadir, and factors that predict DMFS include perineural invasion, risk group, and PSA nadir. CONCLUSIONS: Patients with favorable intermediate-risk cancer could likely be treated with dose-escalated radiation therapy without ADT. Patients with high-risk and unfavorable intermediate-risk cancer, perineural invasion, and PSA nadir ≥1ng/dL had worse outcomes and likely need distinct therapeutic approaches.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Gadia R, Teixeira Leite ET, Bierrenbach AL, et al. Long-term outcomes of dose-escalated intensity modulated radiation therapy alone without androgen deprivation therapy for patients with intermediate and high-risk prostate cancer. Adv Radiat Oncol. 2016. PMID: 28740901. doi:10.1016/j.adro.2016.10.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。